Company
Arcellx, Inc. (ACLX)
Standardized SEC financial data for Arcellx, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001786205 · NASDAQ · Biological Products, (No Diagnostic Substances).
Operating margin
-1000.0%
Net margin
-1000.0%
Revenue growth (YoY)
-79.3%
Return on equity
-56.9%
Free cash flow
-$212.6M
Current ratio
4.43×
EPS (diluted)
$-4.07
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $110.3M | $107.9M | $22.3M |
| R&D expense | $46.9M | $149.6M |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $46.8M | $31.0M | $254.8M | $398.9M | $108.3M | $82.9M |
| Total current assets |
Cash flow
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$54.2M | -$99.3M | $207.6M | -$83.5M | -$210.3M |
| Capital expenditures | $5.8M | $2.3M |
Get ACLX data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/ACLX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/ACLX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"